At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 14 enrolled
Drug / intervention
Clenbuterol Hydrochloride +1 moredrug
Likely dose
Clenbuterol Hydrochloride 40 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting the Beta-2-adrenergic Pathway to Improve Skeletal Muscle Glucose Uptake in Obese Humans
In Brief
A Phase 2 clinical trial evaluating Clenbuterol Hydrochloride and Placebo for Type 2 Diabetes. Completed, enrolled 14 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the effect of four weeks clenbuterol/placebo supplementation on skeletal muscle glucose disposal in overweight/obese male and (postmenopausal) female volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesNetherlands
CollaboratorsEurostars
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartAug 2022
Primary CompletionMar 2024
TodayJul 2026
First PostedJun 10, 2021
Enrollment StartAug 16, 2022
Primary CompletionMar 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.1 years ago
Interventions
Clenbuterol Hydrochloridedrug
Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 28 days with a wash-out period of at least 6-8 weeks.
Placebodrug
Daily ingestion of placebo capsules for a total period of 28 days with a wash-out period of at least 6-8 weeks.